4 Small Cap Stocks To Watch: MWOG Up Over 1,000% Early This Morning

NEW YORK, NY / ACCESSWIRE / April 27, 2016 / The OTC Expert is issuing a report on four stocks that are trading with heavier than usual volume. MWOG, ASTI, TPIV and PPCH are on high volume watch, particularly MWOG. Continue reading to find out why these stocks are getting so much interest today. – If you want reports on the day’s hottest stocks (NYSE/Nasdaq/OTC) subscribe to our newsletter at otc-expert.com.

Midwest Oil and Gas Inc. (OTC: MWOG) Is an exploration stage company that engages in the exploration, development, and production of onshore oil and natural gas reserves.

Shares of MWOG are trading higher by over 600% pre-market this morning and is showing a $0.39 cent gap in share price from its previous close. After the market opened, the stock doubled from its pre-market high and is now trading higher by almost 1,300%.

The stock is bringing in a lot of volume compared to its average volume and this extra attention probably won’t go unnoticed.

Subscribe Free To Receive Alerts Like These Sent To Your Inbox Get Your Free Membership Now.

Ascent Solar Technologies, Inc. (NASDAQ: ASTI) Is a development stage company that designs and manufactures photovoltaic integrated consumer electronics; and portable power applications for commercial and military users.

Shares of ASTI have been relatively stagnant in April and appear to be trending lower. After a big day in mid march, the stock has continued a trend of downward action.

As volume continues to get lighter on this stock, chances are it will continue to drop, however, the stock is known to have big short-term bursts in share price and volume.

Like What You See? Get These Alerts and Many More on NASDAQ Companies before They Rally, Find Out More Here.

TapImmune, Inc. (OTCQB: TPIV) Is a clinical-stage immunotherapy company that develops peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and infectious diseases.

Shares of TPIV traded higher yesterday off heavier than usual volume after AstraZeneca announced that they were increasing their immune-oncology with TPIV.

A joint AstraZeneca-TapImmune Phase 2 ovarian cancer trial will start this quarter at the prestigious Sloan Kettering Institute, according to a press release issued a few days ago.

We are watching TPIV to see if it can hold on to and build off of yesterday’s gains.

Get the Information You Need To Stay Informed and Up To Date On The Hottest NASDAQ Plays Get Them Here.

Propanc Health Group Corporation (OTCQB: PPCH) Is a development stage healthcare company, focuses on the development of cancer treatments for patients with pancreatic and colorectal cancer in Australia.

Shares of PPCH traded higher yesterday by over 16% and the stock has been on a steady rise ever since announcing last week that it had filed two more patent applications in the United States regarding new compositions of its lead product, PRP, for treating cancer.

In early March, PPCH received an influx of share volume that pushed the stock higher by 500%. PPCH received a similar amount of volume the last few trading periods and it is looking like that kind of momentum could continue throughout the rest of the week.

NASDAQ Stock Alerts: Check Them Out Here To Receive Our Winning NASDAQ & NYSE Stock Alerts For Free.

About otc-expert.com

The OTC Expert is a newsletter alert service that focuses on companies on the NASDAQ & NYSE. We only highlight quality companies with big news on high volume days. This commitment provides our subscribers with only the best recommendations of companies for short and long-term investments.

To receive free text message alerts on your phone, compose a new text message to the number 95577 with the word “OTCLEADER”.

Disclosure: The information, opinions and analysis contained in this report are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We do not accept any responsibility or liability for any losses, damages or costs arising from an investor’s or other person’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities, nor a recommendation of any security. Past gains are not representative of future gains. The OTC Expert has not been compensated nor does it expect to receive any compensation for distribution of its opinions and publicly available information regarding the companies reported in this investment opinion article at this time. The opinions contained herein contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. When used herein, the words “anticipate,” “intend,” “estimate,” “believe,” “expect,” “plans,” “should,” “potential,” “forecast,” and variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A company’s actual results could differ materially from those described in any forward-looking statements contained herein. The OTC Expert is not a licensed broker, broker dealer, market maker, investment advisor, analyst or underwriter. We recommend that you use the information found herein as an initial starting point for conducting your own research in order to determine your own personal opinion of the companies discussed herein before deciding whether or not to invest. You should seek such investment, tax, financial, accounting or legal advice appropriate for your particular circumstances. Information about many publicly traded companies and other investor resources can be found at www.sec.gov. Investing in securities is speculative and carries risk. Please visit otc-expert.com/disclaimer website for a more detailed discussion of risks and disclosures.

Contact:

Justin Skibinski
The OTC Expert
info@otc-expert.com

SOURCE: The OTC Expert

ReleaseID: 439278